The FDA Approved Moderna's mRNA Flu Shot for Seniors Without Proving It Works in Them

Accelerated approval was built for serious and life-threatening disease. It is the pathway the FDA created for cancer drugs and HIV therapies, the cases where a patient cannot wait years for a survival curve to resolve, so the agency accepts a surrogate, a lab marker that stands in for the outcome that actually matters, and lets the drug onto the market on the manufacturer’s promise to prove the benefit later. It is a tool for people who are out of time. On August 5 the FDA reached for it to clear a seasonal flu shot for healthy retirees.

The agency approved Moderna’s mFlusiva, formerly mRNA-1010, the first mRNA influenza vaccine ever cleared in the United States. Adults 50 to 64 got full, standard approval. Adults 65 and older, the group that fills the hospitals and the morgues every flu season, got only accelerated approval, with Moderna agreeing to run a confirmatory trial after the fact to find out whether the shot protects them. The order of operations matters here: the people with the most to lose were put first in line for the version whose benefit has not been shown, only promised.

This is the second time in six months the agency has looked at essentially the same package, and the reversal between the two looks is worth slowing down for, because no new evidence forced it. In February the FDA’s head of biologics, Vinay Prasad, issued a refusal-to-file letter, declining even to review the application, because Moderna’s roughly 40,000-person trial had not tested the shot against the high-dose formulation the FDA recommends for seniors. That is a substantive objection: the trial never measured the vaccine against the standard of care for the exact population now getting accelerated approval. About a week later, after Moderna disclosed the rejection and pushed back, the agency accepted a “revised regulatory approach,” and the no became a yes. The trial did not change. The data did not improve. The regulatory posture did. Prasad left the FDA at the end of April.

So look at what the shot actually does, because the headline number and the real number are not the same number. Moderna and regulators cite a relative efficacy of roughly 27 percent against confirmed influenza, and in a press release 27 percent reads like a wall of protection. It is a relative figure. In Moderna’s own Phase 3 trial of mRNA-1010, the absolute rate of PCR-confirmed influenza-like illness fell from about 2.8 percent in the standard-shot group to about 2.0 percent in the mRNA group. That is a reduction, but it is eight tenths of one percentage point. To prevent a single additional case of flu illness, you have to vaccinate well over a hundred people.

And you buy that thin margin at a measurable cost in reactogenicity, which is exactly what the mechanism predicts. Most standard flu shots deliver inactivated virus or a purified protein and are done. An mRNA shot hands your own cells a genetic instruction and turns them into temporary antigen factories, and that process, the lipid nanoparticle plus the sustained protein production, tends to light up the innate immune system harder. It shows up in the trial tables, and not only Moderna’s. Pfizer’s competing modRNA flu vaccine, tested in 18,476 adults and funded by Pfizer, produced local reactions in 70.1 percent of recipients versus 43.1 percent on a standard shot, systemic symptoms in 65.8 percent versus 48.7 percent, and fever in 5.6 percent versus 1.7 percent. Most of it was mild and cleared in a day or two. But the signature is consistent when the platform is aimed at flu: more arm pain, more fatigue, more fever, for a sliver of extra protection. Moderna’s own file carries the same higher rate of severe short-term reactions against its standard-dose comparator.

We have also already seen what happens when the mRNA flu component gets folded into a bigger product. In Moderna’s combination COVID-and-flu shot, the flu half fell short of full protection, a reminder that raising antibodies in a lab assay, the kind of surrogate an accelerated approval leans on, is not the same as keeping an actual 70-year-old out of the hospital in February.

There is a deeper strangeness the trade-press coverage mostly skipped. This approval landed inside an administration whose own health department is walking away from the platform. HHS Secretary Robert F. Kennedy Jr. canceled 22 mRNA vaccine development projects and pulled roughly half a billion dollars in federal mRNA research funding, on exactly the safety-and-benefit questions this flu shot raises. One arm of the government is defunding mRNA vaccine development while another accelerates an mRNA flu vaccine to market for seniors, over the documented objection of the reviewer assigned to it. That is not coordinated policy. It is an agency that reversed itself in a week, and a reviewer who is no longer there to object.

The accelerated-approval pathway is itself the admission, written into the label: the benefit in people over 65 has not been shown, only promised. So watch that confirmatory trial in the 65-and-older group. Watch when it reports, and watch its comparator, whether Moderna is finally made to test mRNA-1010 against the high-dose senior shot Prasad flagged as missing, or against a weaker product that flatters the result. Moderna expects mFlusiva on pharmacy shelves for the 2026-2027 season. The data that is supposed to justify putting it in the oldest arms will arrive, if it arrives, after those arms have already been vaccinated.

Sources

1. STAT – FDA approves Moderna’s mFlusiva, first mRNA flu vaccine (Aug 5, 2026)
2. Healthcare Dive – FDA approves Moderna’s mRNA flu vaccine (age-split approval basis)
3. CBS News – FDA approves Moderna mRNA flu vaccine after initial pushback
4. ScienceDirect – Phase 3 randomized safety and immunogenicity trial of mRNA-1010
5. PubMed – Efficacy, immunogenicity, and safety of Pfizer modRNA influenza vaccine (NCT05540522)
6. JAMA (2024) – Combo COVID-19 and flu mRNA vaccine falls short of total flu protection
7. FierceBiotech – CBER director Vinay Prasad to depart FDA at the end of April
8. CBS News – RFK Jr. halts $500 million for mRNA vaccine research